Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form

Mol Pharm. 2021 Sep 6;18(9):3588-3600. doi: 10.1021/acs.molpharmaceut.1c00485. Epub 2021 Aug 22.

Abstract

In this study, the phase diagram of the ternary system of ezetimibe-simvastatin-fenofibrate was established. It has been proven that the ternary composition recommended for the treatment of mixed hyperlipidemia forms a eutectic system. Since eutectic mixtures are characterized by greater solubility and dissolution rate, the obtained result can explain the marvelous medical effectiveness of combined therapy. Considering that another well-known method for improving the aqueous solubility is amorphization, the ternary system with eutectic concentration was converted into an amorphous form. Thermal properties, molecular dynamics, and physical stability of the obtained amorphous system were thoroughly investigated through various experimental techniques compared to both: neat amorphous active pharmaceutical ingredients (considered separately) and other representative concentrations of ternary mixture. The obtained results open up a new way of selecting the therapeutic concentrations for combined therapies, a path that considers one additional variable: eutecticity.

Keywords: amorphous pharmaceuticals; eutectic system; ezetimibe; fenofibrate; physical stability; simvastatin; ternary eutectic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticholesteremic Agents / chemistry*
  • Anticholesteremic Agents / therapeutic use
  • Chemistry, Pharmaceutical
  • Drug Combinations
  • Drug Compounding / methods
  • Drug Stability
  • Drug Storage
  • Ezetimibe / chemistry*
  • Ezetimibe / therapeutic use
  • Fenofibrate / chemistry*
  • Fenofibrate / therapeutic use
  • Humans
  • Hyperlipidemias / drug therapy
  • Simvastatin / chemistry*
  • Simvastatin / therapeutic use

Substances

  • Anticholesteremic Agents
  • Drug Combinations
  • Simvastatin
  • Ezetimibe
  • Fenofibrate